Lead Plaintiff Deadline: September 12, 2022
Please Upload related files below
Fill in below.
Looking for more?
: (a) American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021; and/or (b) securities between June 16, 2021, and April 26, 2022
(i) the Company’s product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (iii) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (iv) another of the Company’s product candidates, MP0310, was less attractive to Molecular Partners’ collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company’s initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
In order to be included in the lawsuit, you must have incurred a loss on shares of Molecular Partners purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.
If you suffered a loss in Molecular Partners during the relevant time frame or pursuant to the relevant offering(s), you have until September 12, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.